Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603407 | 0.80 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL25723117 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL18155849 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL3782563 | 0.76 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL17970231 | 0.76 | ALDH1A1 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL18049884 | 0.73 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL18049885 | 0.73 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL13594764 | 0.73 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL15218458 | 0.73 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 | |
| SCHEMBL24597145 | 0.73 | HSD11B1 (0.44) | CYP2D6SMN1; SMN2NEK2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | CDK2, CDK4, CCNI | CYP2D6 682/4885SMN1; SMN2 1848/4885NEK2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.